CymaBay Therapeutics Has Commenced An Underwritten Public Offering Of An Aggregate Of $150M Of Its Common Stock And Pre-funded Warrants
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics has started an underwritten public offering of an aggregate of $150M of its common stock and pre-funded warrants.
September 11, 2023 | 10:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CymaBay Therapeutics' public offering of $150M of its common stock and pre-funded warrants may dilute existing shareholders' equity.
Public offerings often lead to dilution of existing shareholders' equity, which can negatively impact the stock price in the short term. However, the funds raised can be used for growth and expansion, which could have a positive impact in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100